Theranostics Market Size, Share, Trends, Industry Analysis Report: By Product Type (Instruments, Reagents, and Software), Application, Technology, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Apr-2025
- Pages: 116
- Format: PDF
- Report ID: PM1295
- Base Year: 2024
- Historical Data: 2020-2023
Theranostics Market Overview
The theranostics market size was valued at USD 2,049.68 million in 2024. The market is projected to grow from USD 2,362.26 million in 2025 to USD 8,640.97 million by 2034, exhibiting a CAGR of 15.5% during 2025–2034.
The theranostics market refers to the integration of therapeutic and diagnostic approaches to provide personalized treatments, particularly in the field of precision medicine. It combines the use of diagnostic tests, such as imaging and biomarker assays, with targeted therapies to optimize patient outcomes.
Key drivers of the theranostics market demand include advancements in personalized medicine, increasing demand for precision healthcare, and the growing adoption of molecular diagnostics and biomarkers in clinical settings. Additionally, the development of innovative technologies, such as companion diagnostics and targeted drug delivery systems, is contributing to market growth. Theranostics market trends indicate a rising focus on the use of theranostics in oncology, where it has shown promise in improving treatment efficacy and reducing side effects.
To Understand More About this Research: Request a Free Sample Report
Theranostics Market Dynamics
Advancements in Personalized Medicine
One of the key drivers of the theranostics market development is the continued advancements in personalized medicine. The shift toward precision healthcare, which tailors treatments based on an individual's genetic makeup, lifestyle, and other factors, has led to an increasing demand for targeted therapies and diagnostics. This personalized approach improves treatment efficacy and minimizes adverse effects. The development of genomic and molecular diagnostic tools enables more accurate identification of disease biomarkers. In oncology, precision therapies based on genetic profiling have shown significant potential in improving treatment outcomes. According to a report from the National Cancer Institute, personalized therapies have been shown to increase the survival rate for some cancer types by up to 30%. This growing focus on individualized treatment plans is expected to continue driving the theranostics market growth.
Rising Adoption of Molecular Diagnostics
The increasing adoption of molecular diagnostics is another major driver behind the theranostics market growth. Molecular diagnostics allow for the detection and monitoring of specific biomarkers associated with diseases at the molecular level, which can be critical for early diagnosis and targeted treatment. As technologies improve and become more widely accessible, the integration of molecular diagnostics with therapeutic options is expanding, propelling market expansion.
Technological Innovations in Companion Diagnostics
Technological innovations in companion diagnostics (CDx) are significantly influencing the theranostics market opportunities. Companion diagnostics are tests designed to predict the effectiveness of a specific therapeutic intervention, ensuring that the right patient receives the right treatment. The development of more advanced companion diagnostic tests, which use genetic, genomic, or proteomic markers to determine the most suitable therapy, is expanding rapidly. The approval of several targeted therapies, such as those used in oncology for breast cancer or lung cancer, has been closely linked with the use of companion diagnostics to ensure therapeutic efficacy. This rise in approval and use of CDx is driving the demand for integrated theranostics, particularly as precision medicine becomes more prominent in clinical practices.
Theranostics Market Segment Insights
Theranostics Market Assessment by Product Type
The theranostics market, based on product type, is segmented into instruments, reagents, and software. Among these, the reagents segment held the largest market share in 2024, primarily due to the critical role they play in diagnostic tests, including biomarker assays and molecular diagnostic applications. Reagents are essential for performing the various diagnostic tests that guide the development of personalized therapeutic strategies. This segment benefits from the increasing demand for precision medicine, as well as advancements in molecular diagnostics. The growth of the reagents segment is further supported by the ongoing development of new biomarker-based assays that enable more accurate disease detection, particularly in oncology.
The software segment is registering the highest growth within the theranostics market, driven by the increasing reliance on data analytics and artificial intelligence to interpret diagnostic results and inform treatment decisions. Software platforms that integrate diagnostic information with therapeutic protocols are becoming essential for providing personalized care. These platforms enhance the efficiency of theranostics procedures, helping clinicians make more informed decisions. The software segment is expected to continue its rapid expansion as healthcare systems increasingly adopt digital technologies to optimize patient outcomes.
Theranostics Market Assessment by Application
The theranostics market, by application, is segmented into oncology, neurology, cardiology, and infectious diseases. The oncology segment dominated the theranostics market share in 2024 due to the increasing prevalence of cancer globally and the growing adoption of targeted therapies for the disease treatment. Theranostics has gained significant traction in oncology, particularly through the use of molecular diagnostics to identify genetic mutations, enabling personalized treatment plans. Advances in cancer diagnostics and the development of targeted therapies that are paired with companion diagnostics have significantly contributed to the segment’s dominant position. The use of theranostics in oncology is expected to continue expanding, driven by ongoing research and the increasing availability of personalized cancer treatments.
The neurology segment, while smaller in comparison, is registering the fastest growth. The rise in neurodegenerative diseases, such as Alzheimer's and Parkinson's, combined with the development of diagnostic tools for early detection and personalized treatment, is driving this growth. Advances in imaging technologies and molecular biomarkers for neurological disorders are key factors fueling the demand for theranostics in this segment.
Theranostics Market Evaluation by Technology
The theranostics market, based on technology, is segmented into genomics, proteomics, metabolomics, and biomarkers. The genomics segment accounted for a major market share in 2024 due to the growing demand for genomic-based diagnostics and targeted therapies. The ability to sequence and analyze an individual's genetic makeup enables the identification of specific biomarkers associated with various diseases, particularly in oncology. Genomic technologies, such as next-generation sequencing (NGS), have revolutionized the approach to precision medicine, allowing for more accurate diagnoses and the development of personalized treatment strategies. The widespread adoption of genomic diagnostics in clinical settings is expected to continue supporting the dominance of this segment, particularly as the cost of genomic testing continues to decrease, making it more accessible to healthcare providers.
The proteomics segment is registering the fastest growth, fueled by advancements in technologies that enable the detailed study of proteins and their functions in disease processes. Proteomics plays a critical role in identifying novel biomarkers and understanding disease mechanisms, which is vital for the development of targeted therapies. The increasing integration of proteomic analysis with diagnostic and therapeutic tools is propelling the segment growth, with healthcare systems focusing on improving the precision of disease detection and treatment outcomes.
Theranostics Market Assessment by End User
The theranostics market, by end user, is segmented into hospitals, diagnostic laboratories, and research institutes. The hospital segment dominated the theranostics market revenue share in 2024, driven by the central role hospitals play in patient care and their ability to integrate advanced diagnostic and therapeutic technologies. Hospitals are increasingly adopting theranostics solutions to offer personalized treatments, particularly in areas such as oncology and cardiology, where precision medicine has proven to be highly effective. The integration of theranostics tools, including molecular diagnostics and imaging technologies, enables hospitals to provide more accurate diagnoses and tailor treatment plans to individual patients, improving overall clinical outcomes. This growing trend toward personalized medicine in hospitals is expected to boost the segment's market position.
The diagnostic laboratories segment is registering the fastest growth, fueled by the rising demand for early disease detection and personalized treatment strategies. The growing prevalence of chronic diseases and the increasing reliance on diagnostic testing for early intervention are key factors driving the growth of the segment. Additionally, the expansion of diagnostic services in developed and emerging markets supports the rapid adoption of theranostics in laboratories.
Theranostics Market Regional Outlook
By region, the report provides theranostics market insight into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the largest theranostics market share in 2024, primarily driven by the strong presence of advanced healthcare infrastructure, high adoption of precision medicine, and significant investments in research and development. The region benefits from the widespread availability of molecular diagnostics, companion diagnostics, and targeted therapies, particularly in oncology. The presence of major pharmaceutical and biotechnology companies, along with favorable regulatory policies supporting personalized medicine, further strengthens market growth. Additionally, increasing cancer prevalence and the rising demand for early disease detection contribute to the theranostics market expansion in the region.
Europe is a significant market for theranostics, driven by increasing investments in precision medicine, strong regulatory support, and the rising prevalence of chronic diseases such as cancer and neurological disorders. Countries such as Germany, the UK, and France are at the forefront of theranostic adoption, benefiting from well-established healthcare infrastructures and ongoing research initiatives. The region has witnessed a growing emphasis on integrating companion diagnostics with targeted therapies, particularly in oncology. Additionally, government initiatives promoting biomarker research and personalized treatment approaches are further supporting theranostics market expansion.
The Asia Pacific theranostics market is registering the fastest growth, fueled by the rapid development of healthcare infrastructure, increasing prevalence of chronic diseases, and growing investments in biotechnology and molecular diagnostics. Countries such as China, Japan, and India are leading the region’s expansion due to rising healthcare expenditures and greater adoption of precision medicine. The increasing availability of advanced diagnostic technologies and government support for personalized medicine initiatives are further driving market growth. Additionally, the rising demand for early disease detection and targeted therapies is accelerating the adoption of theranostics across the region.
Theranostics Market – Key Players and Competitive Analysis Report
The theranostics market comprises several active companies contributing to advancements in personalized medicine. A few notable participants include Advanced Accelerator Applications; Bayer AG; GE HealthCare Technologies Inc.; Siemens Healthineers AG; Cardinal Health, Inc.; Lantheus Holdings, Inc.; Curium Pharma; Abbott Laboratories; Thermo Fisher Scientific Inc.; Astellas Pharma Inc.; F. Hoffmann-La Roche AG; and Illumina, Inc.
These companies are actively engaged in developing and commercializing theranostic solutions, integrating diagnostic and therapeutic capabilities to enhance patient outcomes. For instance, Siemens Healthineers AG has expanded its molecular imaging portfolio through strategic acquisitions, such as the recent purchase of Advanced Accelerator Applications from Novartis AG. Similarly, Lantheus Holdings, Inc. has strengthened its position in the market by acquiring global rights to Life Molecular Imaging's novel radiopharmaceuticals, aiming to broaden its oncology offerings.
In this competitive landscape, companies are focusing on innovation and strategic collaborations to maintain and grow their market presence. Investments in research and development are pivotal, with an emphasis on creating targeted therapies and companion diagnostics. Additionally, partnerships and acquisitions are common strategies to enhance product portfolios and expand geographic reach. As the demand for personalized medicine continues to rise, these companies are well-positioned to address the evolving needs of healthcare providers and patients.
Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, is a global company in life sciences and clinical research, offering a comprehensive portfolio of analytical instruments, laboratory reagents, consumables, and diagnostic solutions. Formed in 2006 through the merger of Thermo Electron and Fisher Scientific, the company has since expanded its capabilities through strategic acquisitions such as Life Technologies Corporation and PPD. Thermo Fisher serves diverse sectors, including pharmaceuticals, biotechnology, healthcare, and environmental sciences. The company contributes to theranostics market through advanced technologies such as polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing (NGS). These tools are critical for identifying biomarkers and tailoring treatments for diseases such as cancer.
GE HealthCare Technologies Inc., a prominent global provider of medical technology, pharmaceutical diagnostics, and digital healthcare solutions, is dedicated to advancing personalized and connected care. With a legacy of over 100 years, the company serves more than one billion patients annually, supported by an installed base of over four million devices. GE HealthCare invests over $1 billion annually in research and development, driving innovation across its four key business segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its offerings span diagnostic imaging systems such as CT, MRI, and molecular imaging, as well as AI-enabled digital solutions that enhance clinical insights and operational efficiency. GE HealthCare’s commitment to theranostics reflects its broader focus on precision medicine, where real-time diagnostics are paired with tailored treatments to improve outcomes for complex diseases like cancer.
List of Key Companies in the Theranostics Market
- Abbott Laboratories
- Advanced Accelerator Applications
- Astellas Pharma Inc.
- Bayer AG
- Cardinal Health, Inc.
- Curium Pharma
- F. Hoffmann-La Roche AG
- GE HealthCare Technologies Inc.
- Illumina, Inc.
- Lantheus Holdings, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
Theranostics Industry Developments
- In September 2024, Icon Group announced the launch of theranostics research program, increasing access to precision medicine and advanced clinical trials, providing more hope and opportunity to cancer patients globally.
- In June 2024, The Theranostics Trial Center (TTC) was inaugurated as a new section within the Department of Nuclear Medicine and Hospital Physics, Medical Diagnostics Karolinska (MDK) to support clinical trials of radiolabeled targeted drugs for diagnosing and treating cancer patients.
- In October 2023, Icon Group, one of the largest dedicated cancer care provider, announced a major advancement in their comprehensive cancer treatment service with the launch of theranostics.
Theranostics Market Segmentation
By Product Type Outlook (Revenue – USD Million, 2020–2034)
- Instruments
- Reagents
- Software
By Application Outlook (Revenue – USD Million, 2020–2034)
- Oncology
- Neurology
- Cardiology
- Infectious Diseases
By Technology Outlook (Revenue – USD Million, 2020–2034)
- Genomics
- Proteomics
- Metabolomics
- Biomarkers
By End User Outlook (Revenue – USD Million, 2020–2034)
- Hospitals
- Diagnostic Laboratories
- Research Institutes
By Regional Outlook (Revenue – USD Million, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Theranostics Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 2,049.68 million |
|
Market Value in 2025 |
USD 2,362.26 million |
|
Revenue Forecast by 2034 |
USD 8,640.97 million |
|
CAGR |
15.5% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
How is the report valuable for an organization?
Workflow/Innovation Strategy: The theranostics market has been broadly segmented on the basis of product type, application, technology, and end user. Moreover, the study provides the reader with a detailed understanding of the different segments at both the global and regional levels.
Growth/Marketing Strategy: Companies in the theranostics market focus on expanding their product portfolios through research and development, strategic collaborations, and acquisitions to strengthen their presence in precision medicine. Investments in biomarker discovery, molecular diagnostics, and targeted therapies drive innovation and market growth. Regulatory approvals and reimbursement policies play a crucial role in market expansion, influencing the adoption of theranostics solutions. Additionally, partnerships between pharmaceutical companies, diagnostic firms, and healthcare providers help in integrating theranostics into clinical practice. Market players also emphasize geographic expansion, particularly in emerging markets, to tap into the growing demand for personalized medicine.
FAQ's
The theranostics market size was valued at USD 2,049.68 million in 2024 and is projected to grow to USD 8,640.97 million by 2034.
The market is projected to register a CAGR of 15.5% during the forecast period.
North America held the largest share of the market in 2024.
The theranostics market comprises several active companies contributing to advancements in personalized medicine. A few notable participants include Advanced Accelerator Applications; Bayer AG; GE HealthCare Technologies Inc.; Siemens Healthineers AG; Cardinal Health, Inc.; Lantheus Holdings, Inc.; Curium Pharma; Abbott Laboratories; Thermo Fisher Scientific Inc.; Astellas Pharma Inc.; F. Hoffmann-La Roche AG; and Illumina, Inc.
The reagents segment accounted for the largest share of the market in 2024.
The oncology segment accounted for the largest share of the market in 2024.
Theranostics is a medical approach that combines diagnostic testing and targeted therapy to provide personalized treatment for patients. It involves using specific diagnostic tools, such as molecular imaging and biomarker analysis, to identify disease characteristics and then applying tailored therapies based on these findings. This approach is widely used in oncology, neurology, and other fields to improve treatment precision, minimize side effects, and enhance patient outcomes. By integrating diagnostics and therapy, theranostics enables real-time monitoring of treatment effectiveness and allows for adjustments to optimize patient care.
A few key trends in the market are described below: Advancements in Molecular Imaging and Biomarkers – Growing use of PET, SPECT, and advanced biomarkers for precise disease diagnosis and treatment monitoring. Increased Adoption of Companion Diagnostics – Rising integration of companion diagnostics with targeted therapies to enhance personalized treatment strategies. Expansion of Radiotheranostics – Increasing use of radiopharmaceuticals in cancer treatment, particularly in prostate and neuroendocrine tumors. Growth in AI and Digital Health Integration – Adoption of artificial intelligence and machine learning for improved data analysis, diagnostic accuracy, and treatment planning.
A new company entering the theranostics market must focus on developing advanced molecular diagnostics, AI-driven data analysis, and next-generation biomarker-based therapies to enhance precision medicine. Investing in radiotheranostics, particularly in oncology applications, could provide a competitive edge due to the increasing demand for targeted radiopharmaceuticals. Strategic collaborations with pharmaceutical and biotechnology firms can accelerate product development and market access. Additionally, prioritizing regulatory compliance and reimbursement strategies will facilitate adoption in clinical settings. Expanding into emerging markets with cost-effective solutions can further strengthen market positioning and growth potential.
Companies manufacturing, distributing, or purchasing theranostics-related products and other consulting firms must buy the report.
© 2025 Polaris Market Research and Consulting. All rights reserved
